and Drug Administration Center for Drug Evaluation and Research
of the FDA’s Center for Drug Evaluation and Research (CDER) is
to assure that safe and effective drugs are available to the public.
Users can easily locate Drug Approvals (CDER New and Generic Drug Approvals
1998-2001) via a browsable chart, and the Electronic Orange Book (Approved
Drug Products with Therapeutic Equivalence Evaluations). CDER posts
warning letters and notice of violation letters to pharmaceutical companies.
Most useful is that researchers can subscribe to a variety of CDER daily
or weekly e-mail lists free of charge.
FDA Recalls and Safety Alerts
FDA’s Recalls and Safety Alerts site provides up-to-date information
on drug recalls and safety alerts. Product recalls and safety alerts
announced over the past 60 days are listed, while various archives include
alerts since 1990. Click on the bottom of the page for the link to the
FDA homepage. There, users can access MedWatch, a current awareness
service of the FDA Safety Information and Adverse Reporting Program.
Safety information is grouped into two groups: (1) drugs, biologics,
devices, and dietary supplements; and (2) drug labeling changes. A link
is provided to relevant articles and publications, and most helpful
is the MedWatch e-list where researchers can subscribe to receive medical
product safety alerts delivered via e-mail.
Pharmacy researchers will find WebMD a convenient site to access, although
it is generally known as a provider of consumer-oriented health information.
Click on “Drugs and Herbs” for information on prescription
medications, over-the-counter medications, and herbal remedies. Researchers
may utilize the search engine or just browse through the alphabetical
listing to read encyclopedic entries. Also accessible is FDA information,
such as the latest FDA Drug Alerts, Product Recalls, New Drug announcements,
and FAQs regarding drug questions.
American Pharmaceutical Association
of the American Pharmaceutical Association’s publications are
available on this site, such as the Journal of the American Pharmaceutical
Association (JAPhA) and Pharmacy Today. The current issue of Pharmacy
Today is online in summary form only; however, JAPhA is provided back
to Nov./Dec. 1998 by table of contents and by abstract, with recent
issues available full text. Most helpful is an extensive collection
of pharmacy practice websites that provide a great starting point for
Findlaw’s Class Action and Mass Tort
of drugs or dietary supplements are listed on this website with the
actions taken regarding their safety. Examples are Fen-Phen, Ephedra,
and Celebrex. The researcher is provided with an overview of the litigation,
along with links to websites focusing on the drug litigation. Findlaw
provides newsletters to notify researchers about current class action
news. Subscribe to Class Action and Recall News and Class Action Case
summaries by filling out a subscription form at this website.